Carrier-free resveratrol nanoparticles: Formulation development, In-vitro anticancer activity, and oral bioavailability evaluation

Resveratrol nanoparticles (RNP) formulation was prepared with 0.5% w/v of SDS and confirmed by TEM, XRD, DSC, XRD, FTIR and NMR. The prepared RNP were evaluated for physicochemical properties like solubility, stability, dissolution profile and partition coefficient. The anticancer activity of prepared RNP formulation was determined against HCT 116 human colorectal cancer cells by cell viability and apoptosis studies. An in vivo pharmacokinetic study in SD rats showed that, the AUC of the RNP was significantly higher (p < 0.0001) than the pure RSV. The plasma Cmax was found to be 0.23 ± 0.02 μg/mL for RSV and 0.62 ± 0.09 μg/mL for RNP. An increase in AUC and Cmax suggested that, the developed formulation was more bioavailable than the pure RSV.